Investors

Corporate Profile

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of our first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of normal hematopoiesis. 

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. 

Ongoing clinical studies of imetelstat consist of IMerge™, a Phase 2/3 trial in lower risk myelodysplastic syndromes (MDS) and IMbark™, a Phase 2 trial in Intermediate-2 or High-risk myelofibrosis.

Recent News

Date Title and Summary  
Toggle Summary Calvin B. Harley to Retire as Chief Scientific Officer of Geron
Continues as Senior Advisor to Company MENLO PARK, Calif., September 8, 2009 - Geron Corporation (Nasdaq: GERN) today announced that Calvin B. Harley, Ph.D., the company's chief scientific officer (CSO) for telomerase technologies, will retire on September 15, 2009. Dr.
Toggle Summary Corning Incorporated and Geron Corporation Showcase New Synthetic Surface Matrices to Enhance Stem Cell Growth
Results of collaborative research to be shared at 2009 World Stem Cell Summit CORNING, N.Y. & MENLO PARK, Calif., September 21, 2009 - Corning Incorporated (NYSE: GLW) and Geron Corporation (Nasdaq: GERN) today announced the successful development of novel synthetic surface matrices demonstrated to
Toggle Summary Data Show Geron´s Cell-Based Therapeutic for Spinal Cord Injury Survives and Exhibits Remyelination for at Least Nine Months Following Injection
Study Also Shows GRNOPC1 Does Not Amplify Neuropathic Pain Like Other Neural Progenitor Cells Injected into Spinal Cord MENLO PARK, Calif., Nov. 7, 2007 – Geron Corporation (Nasdaq: GERN) today announced that data show GRNOPC1, the company’s human embryonic stem cell (hESC)–based therapeutic for

Upcoming Events

More >>
There are currently no events to display.

Corporate Presentation

Documents

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Contact Information

CG Capital
877-889-1972

investor@geron.com